STOCK TITAN
  1. Home
  2. News
  3. CANF

Can-Fite Biopharma Ltd - CANF STOCK NEWS

Welcome to our dedicated news page for Can-Fite Biopharma (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Can-Fite Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Can-Fite Biopharma's position in the market.

News
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Rhea-AI Summary
Can-Fite BioPharma announces the publication of a scientific article by a key opinion leader highlighting Namodenoson as a potential treatment for advanced liver cancer and MASH. The article discusses the drug's mechanism of action and its positive effects in liver cancer and MASH, with ongoing Phase III and Phase IIb trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
-
News
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Rhea-AI Summary
Can-Fite BioPharma submits IND application to FDA for Phase IIb study of Namodenoson in treating MASH, demonstrating positive effects in reducing hepatic steatosis, inflammation, and fibrosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
clinical trial
-
News
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV
Rhea-AI Summary
Can-Fite BioPharma, (CANF) to present at The 14th Annual LD Micro Invitational in New York. CEO Motti Farbstein to lead the presentation on April 9th, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
conferences
News
Can-Fite Reports 2023 Financial Results and Clinical Update
Rhea-AI Summary
Can-Fite BioPharma announced financial results and clinical updates for the twelve months ended December 31, 2023. Ewopharma acquired marketing rights for Namodenoson in the treatment of pancreatic carcinoma. Can-Fite broadened its IP for NASH, received a patent allowance in Canada, and published positive data for Piclidenoson in a Phase III Psoriasis study. Financially, the company reported a decrease in revenues but a decrease in net loss for the year ended December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
earnings
-
News
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Rhea-AI Summary
Can-Fite BioPharma Ltd. announces VP of Business Development to present data from pancreatic and liver cancer programs at BIO-Europe Spring 2024. Can-Fite's pipeline includes Namodenoson for liver and pancreatic cancer, licensed to various companies worldwide, attracting interest from potential partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
none
-
News
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
Rhea-AI Summary
Can-Fite BioPharma Ltd. (CANF) receives a Notice of Allowance from the Canadian Intellectual Property Office for a patent related to treating fatty liver disease with Namodenoson. The company's drug reduced liver fat content, showed anti-inflammatory effects, and decreased body weight in patients with NASH in a successful Phase IIa study. Can-Fite's Namodenoson is licensed for NASH treatment in various territories, and the company also has a distribution agreement for its anti-inflammatory drug, Piclidenoson, for psoriasis treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
News
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
Rhea-AI Summary
Can-Fite BioPharma Ltd. expands its out licensing transaction with Ewopharma AG to include the pancreatic cancer indication for Piclidenoson and Namodenoson. Ewopharma AG paid Can-Fite an upfront payment of US$2.25 million with up to an additional US$40.45 million, plus 17.5% royalties on net sales. The distribution agreement allows Ewopharma AG to market and sell the drugs in CEE countries and Switzerland. Can-Fite is pleased with the expansion and considers it an important transaction for the company's penetration into Ewopharma's territory.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
-
News
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
Rhea-AI Summary
Can-Fite BioPharma Ltd. announces the publication of a phase 3 clinical trial for piclidenoson in plaque psoriasis in the Journal of the European Academy of Dermatology and Venereology. The study met its primary endpoint, showing significant improvement in Psoriasis Area and Severity Index (PASI) scores. The drug demonstrated excellent safety and tolerability and is currently being evaluated in a pivotal Phase III study approved by the FDA and EMA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
clinical trial
-
News
The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
Rhea-AI Summary
Can-Fite BioPharma Ltd. (CANF) reports new data on Namodenoson's potential as an anti-obesity drug, highlighting its ability to reduce body weight and inhibit fat levels. The global obesity treatment market is projected to reach $100 billion by 2030, making Namodenoson a potential contender in this lucrative market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
News
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
Rhea-AI Summary
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) received a positive response from the FDA on the Pediatric Study Plan for the treatment of children suffering from psoriasis with Piclidenoson. The plan aims at registration of Piclidenoson with both the FDA and the EMA for the treatment of plaque psoriasis. There is a high market need for a safe and efficacious drug for the treatment of children who suffer from psoriasis. Can-Fite believes the inclusion of children in one or both of the Phase 3 studies significantly broadens any future market launch potential of the drug.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
Stock CANF logo
Can-Fite Biopharma Ltd

NYSE:CANF

CANF Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CANF Stock Data

10.48M
1.50B
4.89%
0.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
P O Box 7537

About CANF

can fite biopharma (canfy) is a biotechnology company based out of 10 bareket street, פ"ת, israel.